

Quanta to Exhibit at the 56th Annual ERA-EDTA Congress

Alcester, Warwickshire, UK, 11 June 2019: Quanta Dialysis Technologies Ltd ("Quanta" or the "Company"), a pioneering British medical device company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that the Company will be exhibiting at the 56th Annual European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Thursday 13th to Sunday 16th June, at the HUNGEXPO in Budapest, Hungary, at booth number 1.040.

Ahead of commercial launch, planned for Q4 2019, Quanta will be showcasing its updated, state-of-the-art personal haemodialysis system, SC+, designed to offer patients flexibility enabling them to fit treatment around everyday life.

SC+ maintains its small, compact form factor whilst offering patients the latest technology, including a high-resolution touch screen interface designed for simplicity, as well as capabilities enabling integration with digital health solutions.

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Dr. Paul Komenda, Chief Medical Officer, please contact <u>enquiries@quantadt.com</u>.

ERA-EDTA brings together worldwide physicians and kidney specialists to learn and share the latest advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects.

-ENDS-

For more information about Quanta, please contact:

Quanta	
John E. Milad,	T: +44 (0)1789 400043
Chief Executive Officer	E: enquiries@quantadt.com

Consilium Strategic Communications Amber Fennell / Matthew Neal / Lindsey Neville T: +44 (0)203 709 5708 E: guanta@consilium-comms.com

About SC+

SC+ is a small, simple and powerful haemodialysis system designed to provide greater flexibility around where, when and how patients manage and receive their dialysis therapy. As a CE marked medical device, SC+ has been successfully piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users—including patients themselves—to manage dialysis therapy delivery across a wide range of settings—from the clinic to the home.

About Quanta

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Wellington Partners, Seroba Life Sciences, b-to-v Partners, Stage Capital, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company.

For more information, please visit: www.quantadt.com.

SC+ is not yet FDA cleared and not yet available for sale in the USA.